Updating risk prediction tools: a case study in prostate cancer

scientific article

Updating risk prediction tools: a case study in prostate cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/BIMJ.201100062
P932PMC publication ID3715690
P698PubMed publication ID22095849
P894zbMATH Open document ID1239.62130

P50authorDonna AnkerstQ58241772
Alan W PartinQ62089936
P2093author name stringYuanyuan Liang
Ian M Thompson
Daniel W Chan
Ziding Feng
Jacob Kagan
Robin J Leach
Martin G Sanda
John T Wei
Lori Sokoll
Tim Koniarski
P2860cites workAmerican Cancer Society guideline for the early detection of prostate cancer: update 2010Q28274848
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyondQ29614697
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approachQ29614698
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesQ29619614
Multiple imputation of discrete and continuous data by fully conditional specificationQ31118138
Missing covariate data in medical research: to impute is better than to ignoreQ33546257
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessQ33839248
Phases of biomarker development for early detection of cancerQ34311577
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterQ34323096
Estimating the diagnostic likelihood ratio of a continuous markerQ34425390
The influence of finasteride on the development of prostate cancerQ34534815
Decision curve analysis: a novel method for evaluating prediction modelsQ34581068
Predicting prostate cancer risk through incorporation of prostate cancer gene 3.Q34809531
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level aloneQ35924515
Assessing the performance of prediction models: a framework for traditional and novel measuresQ36617895
Estimating the capacity for improvement in risk prediction with a markerQ37090852
Prospective evaluation of operating characteristics of prostate cancer detection biomarkersQ37252155
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerQ39722492
Assessing prostate cancer risk: results from the Prostate Cancer Prevention TrialQ39752227
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened populationQ39778617
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionQ39904254
Projecting individualized absolute invasive breast cancer risk in African American womenQ40149673
A review of goodness of fit statistics for use in the development of logistic regression modelsQ40338804
Decision curve analysis: a discussionQ41976258
A new logistic regression approach for the evaluation of diagnostic test resultsQ43760998
The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10Q46355737
Bayesian inference for finite mixtures of univariate and multivariate skew-normal and skew-t distributions.Q46390591
Projecting individualized probabilities of developing breast cancer for white females who are being examined annuallyQ69396132
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsyQ82228594
P433issue1
P921main subjectprostate cancerQ181257
P6104maintained by WikiProjectWikiProject MathematicsQ8487137
P304page(s)127-142
P577publication date2011-11-17
P1433published inBiometrical JournalQ15720842
P1476titleUpdating risk prediction tools: a case study in prostate cancer
P478volume54

Reverse relations

cites work (P2860)
Q39108831Comparison of approaches for incorporating new information into existing risk prediction models
Q38017952Fracture risk assessment: state of the art, methodologically unsound, or poorly reported?
Q35940811Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators
Q36146528Improving prediction models with new markers: a comparison of updating strategies
Q50107743Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator
Q37279076Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator
Q58796826Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer
Q38881882Key steps and common pitfalls in developing and validating risk models.
Q36093723Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator
Q33672510Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer
Q35996067Prostate cancer risk prediction in a urology clinic in Mexico
Q91899181Quantifying the incremental value of deep learning: Application to lung nodule detection
Q38068114Risk stratification in prostate cancer screening.
Q35013380Tailoring the implementation of new biomarkers based on their added predictive value in subgroups of individuals
Q36185925The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting
Q38211603The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Q40037072The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study
Q59575001Translational Risk Models